Psychedelics and Death

Strassman's UNM Studies (1990–1995)

Rick Strassman conducted the first government-approved clinical research on DMT at the University of New Mexico, administering approximately 400 doses of IV DMT to nearly 60 human volunteers over five years. This was the first psychedelic study approved by the U.S. FDA in over 20 years.

Strassman theorized that the pineal gland may produce DMT endogenously, particularly at or near death, potentially mediating NDE imagery. While this remains an influential hypothesis, direct evidence for pineal DMT release in humans during dying has not been established.

"The most interesting results were that high doses of DMT seemed to allow the consciousness of our volunteers to enter into non-corporeal, free-standing, independent levels of existence." — Rick Strassman, DMT: The Spirit Molecule (2001)

DMT Models the Near-Death Experience (Timmermann et al. 2018)

A landmark placebo-controlled within-subjects study at Imperial College London administered IV DMT to 13 healthy participants, then measured their experiences using the validated Greyson Near-Death Experience Scale.

When compared to 13 gender/age-matched individuals reporting genuine NDEs, DMT-induced NDE scores were statistically comparable (t = 1.85, p = 0.089). No significant differences were found on 15 of 16 NDE items. The single difference: "Did you come to a border or point of no return" scored higher in actual NDEs.

Johns Hopkins DMT Entity Encounter Survey (Davis et al. 2020)

A survey of 2,561 individuals (mean age 32, 77% male) characterized entity encounters during DMT experiences. This remains the largest systematic study of DMT entity phenomenology.

• Entity labels: Most commonly described as "being," "guide," "spirit," "alien," or "helper"
• Attributes: Perceived as conscious, intelligent, benevolent, existing in a real but different dimension
• Communication: 69% received a "message"; 19% received a prediction about the future
• Emotional tone: Despite 41% reporting fear, the dominant emotions were love and kindness
• Ontological shift: More than half of those who identified as atheist before the experience no longer did so afterward
• Personal significance: Rated among the most meaningful, spiritual, and psychologically insightful lifetime experiences

Endogenous DMT in the Dying Brain

In 2019, Dean et al. (University of Michigan) provided the first direct evidence that the mammalian brain synthesizes and releases DMT at physiologically meaningful concentrations.

• Key finding: INMT (the enzyme that synthesizes DMT) transcripts were identified in the cerebral cortex, pineal gland, and choroid plexus of both rats and humans
• Dying brain: A significant increase of DMT levels was observed in rat visual cortex following cardiac arrest — independent of an intact pineal gland
• Concentrations: Extracellular DMT in cerebral cortex was comparable to serotonin and other canonical monoamine neurotransmitters

This finding partially supports Strassman's hypothesis but with an important modification: DMT synthesis during dying appears to be a cortical phenomenon, not exclusively pineal. Whether the quantities produced are sufficient to produce NDE-like phenomenology in humans remains unresolved.

Ayahuasca Entity Encounters and "Other Worlds"

Ayahuasca — a DMT-containing brew combined with MAO inhibitors that allows oral bioavailability — has been used for centuries by indigenous groups of the Western Amazon in shamanic initiation and rites of passage. Entity encounters and journeys to "other worlds" are culturally central to these traditions.

Anthropological perspectives: Among indigenous groups, ayahuasca facilitates culturally prescribed encounters with supernatural beings, ancestors, and spirits. The content of visions varies substantially according to the beliefs of the group, suggesting strong set-and-setting effects on phenomenological content.

Clinical observations: With increasing Western use, entities described include beings perceived as extraterrestrials, angels, nature spirits, and deceased relatives. Users consistently describe the experiences as "hyperreal" — more real than ordinary waking reality — and deliver messages perceived as deeply meaningful.

Convergence with DMT research: Survey data indicates that entity contact experiences are widespread with both smoked/IV DMT and ayahuasca, though ayahuasca experiences tend to be longer (4–6 hours vs. 10–15 minutes) and more narratively structured due to the extended duration.

Neural Correlates of DMT (Timmermann et al. 2019)

EEG studies at Imperial College London revealed that IV DMT markedly reduced oscillatory power in alpha and beta bands while robustly increasing spontaneous signal diversity. At peak experience intensity:

• Delta/theta emergence: Oscillatory activity in these frequency bands correlated with peak visual experience — a pattern also seen in dreaming states
• Increased signal diversity: The brain entered a state of higher entropy, consistent with Carhart-Harris's "entropic brain hypothesis"
• Waking-dream state: The researchers described DMT as producing a "vivid waking-dream state" — a hybrid consciousness between dreaming and wakefulness

Notably, dying brains also show surges in gamma oscillations and signal complexity (Borjigin et al. 2023), suggesting convergent neural dynamics between psychedelic states and the process of dying.

Johns Hopkins: Griffiths et al. 2016

A randomized, double-blind, cross-over trial with 51 cancer patients comparing high-dose (22 or 30 mg/70 kg) versus very low/placebo-like dose (1 or 3 mg/70 kg) of psilocybin, with 5 weeks between sessions and 6-month follow-up.

Depression Outcomes

Anxiety Outcomes

Mystical Experience as Mechanism

The Mystical Experience Questionnaire (MEQ30) high-dose mean was 63.6% of maximum (vs. 26.9% low-dose). Critically, MEQ30 scores correlated significantly with 18 of 20 therapeutic outcome measures. Mediation analysis confirmed: mystical-type psilocybin experience on session day mediated the effect of psilocybin dose on therapeutic outcomes.

NYU: Ross et al. 2016

A double-blind, placebo-controlled, crossover trial with 29 cancer patients receiving single-dose psilocybin (0.3 mg/kg) or niacin placebo, both with psychotherapy.

• Immediate, substantial improvements in anxiety, depression, demoralization, and hopelessness
• Improved spiritual wellbeing and quality of life
• Improved attitudes toward death
• At 6.5-month follow-up: 60–80% maintained clinically significant reductions

NYU 4.5-Year Follow-Up (Agin-Liebes et al. 2020)

The longest follow-up study of psilocybin-assisted therapy for existential distress in cancer patients. Results represent what researchers called "an unprecedented finding in the field of psychiatry."

71–100% of participants attributed positive life changes to the psilocybin experience and rated it among the most personally meaningful and spiritually significant experiences of their lives.

The Mystical Experience Questionnaire and NDE Overlap

The MEQ-30 assesses experiences across four dimensions: mystical unity, positive mood, transcendence of time and space, and ineffability. Research consistently shows significant overlap between psychedelic-induced mystical experiences and NDE phenomenology.

The 2022 Johns Hopkins survey of 3,192 adults found that both psychedelic users (LSD n=904, psilocybin n=766, ayahuasca n=282, DMT n=307) and NDE experiencers (n=933) reported reduced fear of death, lasting personal meaning, spiritual significance, and psychological insight. The parallels held across all four psychedelic substances.

Historical Foundation: The Spring Grove Experiments

Modern psilocybin end-of-life research builds on foundations laid at Spring Grove State Hospital (later Maryland Psychiatric Research Center) in the 1960s–70s, where Stanislav Grof and colleagues treated cancer patients with LSD-assisted psychotherapy.

• Grof treated 60+ cancer patients with LSD doses of 200–500μg
• In a study of 31 patients, 29% showed significant improvement in emotional/mental health scores
• Patients received 10 hours of preparatory therapy and 1–2 hours of integration therapy
• Research ended in 1976 when the political climate made psychedelic research impossible
• The gap between Spring Grove's closure (1976) and modern psilocybin trials (~2006) represents 30 lost years of potential research

Mechanism: How Psilocybin Works on Death Anxiety

Converging evidence points to a multi-level mechanism:

• Receptor level: Psilocin (active metabolite) agonizes 5-HT2A serotonin receptors, triggering downstream changes in neural signaling
• Network level: Significant reduction in default mode network (DMN) activity — the brain network associated with self-referential thinking, ego maintenance, and the narrative self. DMN disruption = temporary ego dissolution
• Experiential level: Ego dissolution enables mystical-type experiences — feelings of unity, transcendence, and sacred connection that directly alter one's relationship to mortality
• Cognitive level: The "brain reboot" allows new patterns of thought to form, breaking rigid, fear-driven cognitive loops about death

The mystical experience appears to be the critical mediator: patients who score higher on the MEQ consistently show greater and more durable therapeutic benefit. It is the quality of the experience, not merely the pharmacological intervention, that drives lasting change.

Long-term Effects and Current Status

As of 2025, psilocybin has not received FDA approval for any indication. However, 134 interventional clinical trials have been listed on ClinicalTrials.gov. Key regulatory milestones:

• 2018: FDA Breakthrough Therapy designation for psilocybin in treatment-resistant depression
• 2019: FDA Breakthrough Therapy designation for psilocybin in major depressive disorder
• 2024: FDA Breakthrough Therapy designation for CYB003 (deuterated psilocybin analog) for MDD
• 54 different conditions are currently targeted in psilocybin clinical trials
• Oregon legalized supervised psilocybin services in 2020 (operational 2023)

Jansen's NMDA Receptor Model (1997)

Karl L. R. Jansen proposed that near-death experiences result from blockade of NMDA receptors by endogenous neuroprotective agents — and that ketamine, as an exogenous NMDA antagonist, can reproduce this entire phenomenology.

NDE Features Reproduced by Ketamine

• Tunnel experiences with dark passages opening to bright light
• Out-of-body sensations and separation from physical form
• Conviction of having died
• Encounters with beings (angels, deceased persons, divine entities)
• Mystical and transcendent states
• Life review experiences
• Sense of timelessness and ineffability
• Feelings of profound peace and calm

The Mechanism: Neuroprotective Cascade

Jansen's model rests on a well-established neurobiological chain:

1. Life-threatening conditions (hypoxia, ischemia, hypoglycemia, seizures) trigger a flood of glutamate — the brain's primary excitatory neurotransmitter
2. Excessive glutamate overactivates NMDA receptors, causing excitotoxic cell death (neurotoxicity)
3. The brain releases endogenous protective agents — including alpha-endopsychosin, a peptide that binds to the PCP receptor site on NMDA channels
4. This neuroprotective blockade produces an altered state of consciousness phenomenologically similar to exogenous ketamine

"30% of normal subjects given ketamine insisted that they had not been dreaming or hallucinating, but that the events had really happened." — Karl Jansen

Ketamine Dose-Response and NDE Depth

Martial et al. 2019: Semantic Similarity Analysis

The largest comparative study of drug experiences and NDEs analyzed semantic similarity between ~15,000 reports linked to 165 psychoactive substances and 625 NDE narratives.

This finding supports the NMDA receptor hypothesis and suggests ketamine could serve as "a safe and reversible experimental model for NDE phenomenology."

Jansen's Evolving Position

Jansen later modified his strictly materialist interpretation:

"I am no longer as opposed to spiritual explanations of these phenomena as this article would appear to suggest... drugs and psychological disciplines such as meditation and yoga may render certain 'states' more accessible." — Karl Jansen, later reflection

He suggested drugs may provide "just another door to a space, and not as actually producing that space" — a shift from "ketamine creates NDE illusions" toward "ketamine opens access to a state that may also occur naturally during dying."

This evolution mirrors a broader pattern in the field: researchers who begin with purely materialist frameworks often find their positions complicated by the depth and consistency of their subjects' experiences.

Ketamine in Palliative Care

Ketamine is increasingly used in palliative care settings, with both analgesic and psychotherapeutic applications:

• Phase II trial: Intranasal ketamine (50–150 mg) showed rapid, robust, partially sustained antidepressant effects in advanced cancer patients
• Pal-KAP program: 30 patients (80% cancer, 13% neurological), median 1.5 medicine sessions at ~0.93 mg/kg IM, with minor adverse effects and no serious events
• Retrospective study: Rapid positive influence on anxiety in palliative care patients
• All 11 studies in a systematic review (including 1 RCT) found antidepressant effects

However, a large research gap remains for ketamine-assisted psychotherapy specifically targeting existential distress (as opposed to depressive symptoms).

The Nature of 5-MeO-DMT Experiences

5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is distinct among psychedelics for its reliable induction of complete ego dissolution — what users describe as "ego death." Found naturally in the venom of the Sonoran Desert toad (Bufo alvarius) and in several plant species, it produces some of the most intense mystical states documented in the psychedelic literature.

Phenomenological Profile

• Ego dissolution: Rapid, complete loss of the usual sense of self; boundaries between "self" and "world" dissolve
• "The Void": Higher doses elicit experiences of formless awareness, emptiness, or infinite space — often described as "the source" or "ground of being"
• White light: Closely associated with ego-death; perception of brilliant, all-encompassing luminosity
• Non-dual awareness: Experience of unity beyond subject-object distinction
• Cosmic love: Many report encountering unconditional love as the fundamental nature of reality
• "Rebirth" phenomena: Following ego death, a sense of being reborn or reconstituted
• Time dissolution: Radical distortion of temporal perception; eternity experienced in minutes

Case Study: NDE vs. 5-MeO-DMT (Frontiers, 2023)

A detailed comparative analysis of a 54-year-old neurosurgeon ("Nikoli") who experienced both a profound NDE during a week-long coma from bacterial meningoencephalitis (NDE Scale score: 29/32) and subsequently inhaled 46mg of vaporized 5-MeO-DMT (NDE Scale score: 9/32).

The subject's own assessment: Despite researchers identifying extensive phenomenological parallels, Nikoli rated the similarity at only 2/10. He characterized the 5-MeO-DMT as "like looking through a peephole" compared to being "fully immersed in the Pacific ocean" of his NDE.

Therapeutic Effects of 5-MeO-DMT

Naturalistic studies across Europe have documented therapeutic potential:

• Improvements in life satisfaction, depression, and anxiety sustained up to 4 weeks post-experience
• Therapeutic benefits positively correlated with the intensity of ego dissolution during the session
• Post-traumatic stress disorder case study showed sustained improvement
• Emerging evidence for neuroplasticity-promoting effects

However, 5-MeO-DMT lacks the controlled clinical trial data that psilocybin has accumulated. Its extreme intensity (onset in seconds, peak at 1–5 minutes) makes clinical management more challenging, and "challenging experiences" including panic, terror, and physical distress are not uncommon.

The "Brain as Filter" Question

The 5-MeO-DMT experience, perhaps more than any other psychedelic, directly confronts the fundamental question of consciousness and death. The complete dissolution of self followed by immersion in a state users describe as "more real than reality" raises what the Frontiers case study authors called the unresolved question:

Does the brain generate consciousness, or does it filter a larger field of awareness? If filtering, then both psychedelic disruption and the process of dying might remove constraints on consciousness rather than creating hallucinations. — Paraphrased from Frontiers in Psychology, 2023

The elaborate nature of NDE phenomenology despite diffuse cortical damage, and the capacity of a 15-minute 5-MeO-DMT experience to produce lasting ontological shifts, both challenge purely reductive explanations — even as neural correlates of these states become increasingly well-characterized.

Two Competing Frameworks

Psychedelics Alter Metaphysical Beliefs (Timmermann et al. 2021)

A study of 866 respondents (prospective survey) + 59 participants (controlled clinical trial) published in Scientific Reports documented how psychedelics change beliefs about the nature of reality.

Specific shifts included increased endorsement of:

• Panpsychism: "Mind, consciousness, or soul is a fundamental quality of all things"
• Transcendentalism: Belief in separate realms of existence
• Dualism: Mind-body separation

Simultaneously, decreased endorsement of materialism and naturalism. These belief changes correlated positively with mental health improvements.

Important caveat: A survey of philosophy professors found no association between psychedelic use and non-materialist views, suggesting the effect may vary across populations with different analytical training.

The Dying Brain: Gamma Surges (Borjigin et al. 2023)

Published in PNAS, this study analyzed EEG and ECG signals in four comatose dying patients before and after withdrawal of ventilatory support.

• Two of four patients exhibited rapid, marked surges of gamma power
• Cross-frequency coupling of gamma waves with slower oscillations
• Increased interhemispheric connectivity in gamma bands
• Surges concentrated in the posterior cortical "hot zone" — a region postulated to be critical for conscious processing
• Connectivity was both local (within temporo-parieto-occipital junctions) and global (to contralateral prefrontal areas)
• Activity was stimulated by global hypoxia and surged further as cardiac conditions deteriorated

These findings are remarkable because they show the dying brain can exhibit more organized, higher-frequency activity than the waking brain in regions specifically associated with conscious experience. The gamma patterns overlap with those seen under DMT and other psychedelics, suggesting convergent neural dynamics.

The AWARE Studies: Consciousness During Cardiac Arrest

Led by Sam Parnia, the AWARE studies represent the largest medical investigations of consciousness during clinical death.

AWARE I (2014)

• 2,060 cardiac arrest cases across 15 hospitals worldwide
• 39% of survivors described perception of awareness during cardiac arrest
• 9% had experiences compatible with NDEs
• 2% exhibited full awareness with explicit recall of seeing and hearing events (out-of-body experiences)
• 46% of those with awareness described mental recollections broader than the typical NDE framework

AWARE II (2023)

• 567 in-hospital cardiac arrests across 25 sites, with real-time EEG and audiovisual testing during CPR
• 53 survivors (9.3%); 28 completed interviews
• ~40% reported perception of consciousness without explicit recall
• ~20% reported features consistent with a "Recalled Experience of Death" (RED)
• ~3% reported overt visual and auditory awareness

The AWARE studies confirm that some form of conscious processing occurs during cardiac arrest in a meaningful subset of patients — even when the brain should, by standard neuroscience, be incapable of supporting consciousness. This finding is difficult to reconcile with simple "dying brain chemistry" explanations.

The Entropic Brain Hypothesis (Carhart-Harris, 2014/2018)

Robin Carhart-Harris's entropic brain hypothesis provides a theoretical framework that bridges psychedelic states, consciousness, and potentially the dying process:

• Within upper and lower limits, the entropy of brain activity indexes the richness of conscious states
• Psychedelics increase brain entropy (more random, less predictable neural activity), expanding the repertoire of conscious states
• Normal waking consciousness is a constrained, high-order state; psychedelics and dying may both release these constraints
• "Primary states" (psychedelic, dreaming, early infancy, psychosis) are characterized by elevated entropy relative to "secondary" (normal waking) consciousness
• The DMN normally constrains consciousness to self-referential patterns; its dissolution under psychedelics (and potentially in dying) opens wider experiential territory

This framework suggests the phenomenological overlap between psychedelic and NDE states may reflect a shared computational principle: disruption of the brain's predictive-processing machinery, revealing consciousness in a less filtered state.

An Honest Assessment: What We Know and Don't Know

What the evidence establishes:

• Psychedelics and NDEs share significant phenomenological overlap, measured with validated instruments
• The overlap is strongest for ketamine (NMDA blockade) and DMT (serotonergic), suggesting multiple neurochemical pathways converge on similar experiential territory
• The dying brain shows paradoxically heightened, organized activity in consciousness-related regions
• DMT is endogenously synthesized in the brain and increases during cardiac arrest in animal models
• Psychedelic experiences durably reduce death anxiety and shift metaphysical beliefs away from materialism

What remains genuinely unknown:

• Whether endogenous DMT reaches psychoactive concentrations in the human dying brain
• Whether the dying brain's gamma surges correlate with subjective experience (we can't ask the dead)
• Whether the phenomenological overlap means psychedelics access the same "space" as dying, or merely activate similar neural circuits for unrelated reasons
• Whether consciousness can exist independent of brain activity (the hard problem remains hard)
• Why only some dying patients report NDEs, and why only some psychedelic users have NDE-like experiences

The deepest question remains unresolved: do psychedelics reveal something about consciousness at death, or do they simulate dying brain chemistry convincingly enough to produce the illusion of transcendence? The evidence is genuinely ambiguous. Both interpretations have sophisticated scientific support, and honest inquiry requires sitting with that ambiguity.

A Life in Psychedelic Science

The Diagnosis

In late 2021, Griffiths was diagnosed with stage 4 colon cancer — the very kind of life-threatening illness his research had addressed. The man who had helped cancer patients find peace through psychedelics now faced his own mortality. Multiple interviews in the final months of his life documented his response.

Facing Death: Griffiths's Personal Testimony

"On one hand, never better — emotionally and spiritually. Medically, not so great." — Roland Griffiths, when asked how he was feeling during his illness

Griffiths described his diagnosis as "a call to celebration." Rather than despair, he found himself in a state of profound gratitude and presence. He credited both meditation and his understanding of psychedelic experiences with helping him navigate his final chapter.

"My parting invitation is to celebrate. I'm inviting you to celebrate what I'm celebrating and that is this experience of the miracle of where we find ourselves. You need not have a terminal diagnosis to lean in more fully, and I promise you it's worth it." — Roland Griffiths, final public message

His personal psychedelic experience: Griffiths initially did not want to take psilocybin during his illness, concerned it might alter the equanimous state he had already reached. He eventually took LSD and used the experience to "interview himself," confirming that the profound aliveness he was feeling was legitimate and that he was "exactly where he needed to be" to handle the reality of his own death.

He approached his death with calm, curiosity, and what he described as "gratitude for the miracle of sentient existence." He died on October 16, 2023, at age 77.

The Researcher's Paradox

Griffiths's life and death embody the central paradox of psychedelic death research. As a scientist, he worked within a materialist framework — designing controlled trials, measuring outcomes, publishing in peer-reviewed journals. Yet the experiences he studied (and ultimately had himself) pointed toward something his methodology could not fully capture.

He did not claim certainty about what happens after death. He did not claim psychedelics prove the existence of an afterlife. What he did demonstrate, through both his research and his personal example, was this:

That this transformation happened not only in his patients but in Griffiths himself — that the researcher's own death validated what his data predicted — is perhaps the most compelling finding in the entire field.

Key Researchers in Psychedelic Death Studies